1. Home
  2. Mandates
  3. Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 125 million

Mandate Vinge has advised Vicore Pharma in connection with a directed share issue of approximately SEK 125 million

November 13, 2019

Vinge has advised Vicore Pharma, a Swedish rare disease company focused on interstitial lung diseases and related indications, in connection with a directed share issue whereby Vicore Pharma will receive approximately SEK 125 million in issue proceeds.

The subscription price was determined to SEK 16 per share through an accelerated book building process. The share issue was directed to a number of Swedish and international institutional investors. The main purpose of the share issue is to finance Vicore Pharma’s development of current and future product candidates. 
Vinge’s team consisted of Jesper Schönbeck, Nils Fredrik Dehlin and Stephanie Stiernstedt.

 

Summary of employment related news in Sweden as of January 2021

 Short-time work, a new pandemic law and pending changes to the Employment Protection Act. Here is the latest employment related news in Sweden.
January 19, 2021

Vinge in first place when the transaction year 2020 is summarized
January 07, 2021

Sanctions round-up

Not so long ago, sanctions were a rare occurrence which only involved obscure products and countries, and which were decided by the members of the United Nations Security Council. Today, the European Union and particularly the United States, impose sanctions and other trade restrictions with high frequency which have the potential to affect any type of transaction. Set forth below is a summary of some recent developments.
December 22, 2020